CG Oncology, Inc. Common stock

CGON

0 Followers
$24.13 +8.01% $1.79
N/A
Upcoming Earnings
 
Market Cap.
 
P/E
Loading...

My Notes

Začít psát

Profile

CG Oncology, Inc. is an American biotechnology company focused on the development of immunotherapeutic drugs for the treatment of cancer. The company specializes in developing therapies that activate the patient's immune system to target and destroy tumor cells. Its leading product is CUE-101, an immunotherapy aimed at treating head and neck cancer. CG Oncology leverages advanced technologies in immunology and oncology to develop innovative treatment approaches for cancer patients who lack sufficient therapeutic options. The company is in clinical development stages, and its common stock is publicly traded on the stock exchange.

Feed

There are no posts to show right now.
Don't have an account? Join us

Log in to Bulios


Or use email and password
Already a member? Log in

Create Bulios profile

Continue with

Or use email and password
You can use lowercase letters, numbers, and underscores

Why Bulios?

One of the fastest growing investor communities in Europe

Comprehensive data on thousands of stocks from around the world

Current information from global markets and individual companies

Education and exchange of investment experience among investors

Fair prices, portfolio tracker, stock screener and other tools

Menu StockBot
Tracker
Upgrade